ICICI Prudential Nifty Pharma Index Fund
ICICI Prudential Mutual Fund · Index Fund · Direct plan, growth option
| Period | Scheme | Category median | Sector: Healthcare & pharma median |
|---|---|---|---|
| 1 month | -1.8% | -6.5% | -2.3% |
| 3 months | 4.6% | -5.1% | 2.2% |
| 6 months | 19.7% | 5.5% | 19.9% |
| Year to date | 16.0% | -6.8% | 15.9% |
| 1 year | 21.2% | -3.0% | 16.4% |
| 3 years (CAGR) | 19.5% | 8.7% | 19.5% |
| 5 years (CAGR) | n/a | 7.6% | n/a |
| 7 years (CAGR) | n/a | 11.1% | n/a |
| 10 years (CAGR) | n/a | 10.9% | n/a |
| Since first NAV (CAGR) | 20.8% | – | – |
“Sector: Healthcare & pharma” is MFIC's grouping of Index Fund schemes by the theme or index in their names, not an AMFI category.
| Measure | Scheme | Category median |
|---|---|---|
| 1Y rolling median | 15.7% | 7.2% |
| 3Y rolling median | 21.8% | 16.3% |
| 3Y rolling worst | 18.9% | 8.4% |
| 3Y periods positive | 100% | 100% |
| 3Y periods ahead of benchmark | n/a | n/a |
| 5Y rolling median | n/a | 13.7% |
| 5Y rolling worst | n/a | 6.4% |
| 5Y periods ahead of benchmark | n/a | n/a |
Benchmark: none available in MFIC's free data for this category.
| Measure | Scheme | Category median |
|---|---|---|
| Standard deviation (ann.) | 15.8% | 17.3% |
| Sharpe ratio | 0.95 | 0.21 |
| Sortino ratio | 1.66 | 0.30 |
| Beta | n/a | n/a |
| Alpha (ann.) | n/a | n/a |
| Upside capture | n/a | n/a |
| Downside capture | n/a | n/a |
| Measure | Scheme | Category median |
|---|---|---|
| Maximum drawdown, full history | −16.6% | −18.8% |
| Maximum drawdown, last 10Y | n/a | −38.1% |
| Maximum drawdown, last 5Y | n/a | −17.6% |
| Current drawdown | −3.2% | −11.0% |
| Recovery time of worst fall | 432 days | – |
Longer histories include more crises, so compare the 5Y and 10Y figures across schemes of different ages.
This scheme aim to track one of the markets below, so its level, valuation and recent path are the main drivers of returns.
- P/E 40.7
- 1Y +21.5% · 3Y +19.9% p.a. · 5Y +13.1% p.a. (index fund NAV, after costs)
- −3.2% from its 52-week high
- P/E 41.9
- 1Y +12.4% · 3Y n/a p.a. · 5Y n/a p.a. (index fund NAV, after costs)
- −5.0% from its 52-week high (proxy NAV)
Index levels and P/E: NSE daily index closing values; gold and silver: IBJA rates; returns: growth NAV of an index fund or ETF tracking the market (AMFI), so they are after that fund's costs. Context only: a market's level or valuation does not tell you how any scheme will perform. Explore all markets.
The Regular plan's expense ratio is 1.18% a year and the Direct plan's 0.51%, a gap of 0.67%; over the last 3 years the Direct plan returned 0.74 percentage points a year more. On a ₹25,000 monthly SIP for 20 years (illustration at 12% a year before costs) the gap adds up to about ₹16,69,441.
With the Regular plan, that cost pays a distributor to help you plan, choose and review funds, and stay invested when markets fall. Whether it is worth it depends on how much of that you will do yourself.
TER: AMFI TER disclosure. Returns: AMFI NAVs. Illustration, not a guaranteed saving or return.
| Fund manager | Role | Managing since |
|---|---|---|
| Nishit Patel | Comanage | 14 Dec 2022 |
| Ashwini Bharucha | Comanage | 18 Dec 2024 |
| Venus Ahuja | 1 Nov 2025 |
Documents: Scheme Information Document · Scheme Summary Document. Read the scheme documents before investing.
| Measure | Scheme | Category median |
|---|---|---|
| Expense ratio (TER), Direct plan | 0.51% | 0.46% |
| AUM, whole scheme (₹ crore) | 163 | 175 |
| Riskometer | Very High | – |
TER: AMFI, TER of MF Schemes. AUM and riskometer: AMFI, Fund Performance, 30 Sep 2026.
| Measure | Scheme | Benchmark / category |
|---|---|---|
| Return, 1 year (AMFI) | 23.4% | 24.0% TRI |
| Return, 3 years (AMFI) | 19.7% | 20.4% TRI |
Official benchmark: Nifty Pharma TRI (total return index, as published by AMFI). Category consistency: last 10 years of month-ends, Index Fund Direct plans; how it is calculated.
| Year | Scheme | Benchmark | Difference |
|---|---|---|---|
| 2026 YTD | 16.0% | n/a | – |
| 2025 | -2.6% | n/a | – |
| 2024 | 38.8% | n/a | – |
| 2023 | 32.9% | n/a | – |
No free benchmark proxy for this category. The first year starts from the first 31 December in the scheme's history.
| Period | Invested | Value | XIRR |
|---|---|---|---|
| 1 year | ₹1,20,000 | ₹1,34,965 | 23.9% |
| 3 years | ₹3,60,000 | ₹4,54,460 | 15.7% |
Uses this plan's NAVs; ignores stamp duty, exit loads and taxes. One historical path only — the interactive SIP analyzer shows outcomes across every start date.
| Scheme | Category | Correlation | 3Y CAGR |
|---|---|---|---|
| Bandhan BSE Healthcare Index Fund | Index Fund | 0.95 | n/a |
| Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund | Index Fund | 0.93 | 18.6% |
| Tata Nifty MidSmall Healthcare Index Fund | Index Fund | 0.93 | n/a |
| ICICI Prudential Nifty Alpha Low - Volatility 30 ETF FOF | Domestic FoF | 0.77 | 8.1% |
| Tata Nifty200 Alpha 30 Index Fund | Index Fund | 0.76 | n/a |
| Nippon India Nifty Alpha Low Volatility 30 Index Fund | Index Fund | 0.74 | 8.2% |
- What is the latest NAV of ICICI Prudential Nifty Pharma Index Fund?
- The NAV of the Direct plan (growth option) was ₹20.3747 on 1 Oct 2026, as published by AMFI.
- Which category is ICICI Prudential Nifty Pharma Index Fund in?
- It is classified as Index Fund in AMFI's daily NAV file; a Index Fund scheme passively tracks a stated index. MFIC compares it with 265 Index Fund schemes (Direct plans).
- What returns has ICICI Prudential Nifty Pharma Index Fund delivered?
- Over one year the NAV changed by 21.2%. The 3-year CAGR is 19.5% (category median 8.7%). Returns are after expenses and before tax. Past performance may or may not be sustained in future.
- How consistent have its 3-year returns been?
- Measuring a 3-year CAGR from every business day in its history, the median was 21.8%, the lowest was 18.9%, and 100% of 3-year periods ended with a gain.
- What was the largest fall in ICICI Prudential Nifty Pharma Index Fund's NAV?
- The largest peak-to-trough fall in its available history was 16.6%.
- How volatile is ICICI Prudential Nifty Pharma Index Fund?
- Its annualised standard deviation of monthly returns over the last 36 months is 15.8%, which is below the Index Fund category median of 17.3%.
- What would a monthly SIP in ICICI Prudential Nifty Pharma Index Fund have grown to?
- A SIP of ₹10,000 on the first business day of each month for the last 3 years (36 instalments, ₹3,60,000 invested) would have been worth about ₹4,54,460 on 1 Oct 2026, an annualised return (XIRR) of 15.7%. This uses the Direct plan's NAVs, ignores taxes and exit loads, and past performance may or may not be sustained in future.
- What is the expense ratio (TER) of ICICI Prudential Nifty Pharma Index Fund?
- The total expense ratio of the Direct plan is 0.51% a year, as disclosed to AMFI (median of Index Fund Direct plans: 0.46%). It is already deducted from the NAV, so every return shown is after expenses.
- How large is ICICI Prudential Nifty Pharma Index Fund?
- Assets under management of the whole scheme were ₹163 crore on 30 Sep 2026, as published by AMFI.
- What is the riskometer level of ICICI Prudential Nifty Pharma Index Fund?
- AMFI lists the scheme's riskometer as “Very High”, and its benchmark's as “Very High”. The riskometer is a label of potential risk set under SEBI rules, not a forecast.
- What is the benchmark of ICICI Prudential Nifty Pharma Index Fund and how has it compared?
- Its official benchmark is the Nifty Pharma TRI. Over 3 years AMFI reports a return of 19.7% for this plan against 20.4% for the benchmark total return index. Past performance does not indicate future results.
- Who manages ICICI Prudential Nifty Pharma Index Fund?
- According to its Scheme Summary Document, ICICI Prudential Nifty Pharma Index Fund is managed by Nishit Patel (since 14 Dec 2022), Ashwini Bharucha (since 18 Dec 2024), Venus Ahuja (since 1 Nov 2025).
- What is the minimum investment in ICICI Prudential Nifty Pharma Index Fund?
- The minimum application amount is Rs. 1000.
- What is the difference between the Direct and Regular plans?
- Both plans hold the same portfolio; the Regular plan includes distribution costs in its expense ratio. Over one year the Direct plan's NAV changed by 21.2% and the Regular plan's by 20.4%. The Regular plan includes the services of a distributor.
Every Monday: this scheme's NAV, 1-month and 1-year return beside its category median, 3-year CAGR and how far it is below its peak. Add more schemes from their pages or from your MFIC watchlist. Free; unsubscribe from any email.